The win ratio approach to analyzing composite outcomes: An application to the EVOLVE trial

Unlike conventional time-to-event analysis of composite endpoints in clinical trials, the “win ratio” method allows for flexibility in prioritizing their components. Here, we compare the EVOLVE trial findings using the win ratio with those from time-to-event analysis. Exposure: Randomization to cina...

Full description

Saved in:

Bibliographic Details
Published in:	Contemporary clinical trials Vol. 48; pp. 119 - 124
Main Authors:	Abdalla, Safa, Montez-Rath, Maria E., Parfrey, Patrick S., Chertow, Glenn M.
Format:	Journal Article
Language:	English
Published:	United States Elsevier Inc 01.05.2016
Subjects:	Aged Angina, Unstable - epidemiology Calcimimetic Agents - therapeutic use Cardiovascular Cause of Death Cinacalcet Cinacalcet Hydrochloride - therapeutic use Composite endpoints EVOLVE trial Female Heart Failure - epidemiology Hematology, Oncology and Palliative Medicine Hospitalization - statistics & numerical data Humans Kidney Failure, Chronic - drug therapy Male Middle Aged Mortality Myocardial Infarction - epidemiology Peripheral Vascular Diseases - epidemiology Proportional Hazards Models Randomized Controlled Trials as Topic Treatment Outcome Win ratio Cinacalcet EVOLVE trial Composite endpoints Win ratio
ISSN:	1551-7144, 1559-2030, 1559-2030
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!